The influence of co-morbidities on prescribing pharmacotherapy for insomnia: evidence from US national outpatient data 1995–2004

Summary

Objective: Patients with insomnia are likely to have other co-morbidities that could affect pharmacotherapeutic choices. This study examined the prevalence and impact of co-morbidities on the pharmacological treatment of insomnia.

Study design: A retrospective data analysis of the National Ambulatory Medical Care Survey from 1995 to 2004, comprising patients with a diagnosis of insomnia, was conducted. Multivariate logistic regression models were used to predict the impact of co-morbidities on pharmacotherapy for insomnia.

Results: A total of 5,487 unweighted patient visits with insomnia were identified, representing 161.4 million patients in the US. Approximately 38% of these patients had at least one co-morbid condition. Patients with mental co-morbidities, especially anxiety, had decreased likelihood of receiving pharmacotherapy for insomnia.

Conclusions: Mental co-morbidities such as episodic mood disorder, anxiety and depression are prevalent in patients with insomnia. However, many co-morbid patients do not receive pharmacological therapy specific for insomnia.     

影响运动员赛前失眠的心理因素及调整措施研究

运动员赛前失眠问题是一个值得重视但并没有得到足够重视和充分研究的课题,赛前失眠发生率高,危害运动员身心健康,直接影响训练和比赛成绩。本文参考相关资料,对运动员赛前失眠进行界定,从心理角度的不同方面分析总结影响运动员赛前失眠的心理因素,针对原因提出各种积极有效的调整措施。对改善赛前失眠群体的失眠症状,提高睡眠质量提供一定的辅助和参考,为运动员在比赛中取得优异成绩储备必需的能量。